Sonrotoclax, sold under the brand name Beqalzi, is an anti-cancer medication used for the treatment of mantle cell lymphoma. It is a BCL-2 inhibitor that can overcome resistance associated with BCL2 mutations, such as the G101V variant, which limits the effectiveness of first-generation inhibitors like venetoclax.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.